Pharmaceutical

Zai Lab and argenx announce NMPA approval for sBLA for VYVGART Hytrulo

Zai Lab and argenx have announced receipt of approval from the National Medical Products Administration (NMPA) of China for the supplemental biologics license application (sBLA) for VYVGART Hytrulo 1,000mg vial for treating chronic inflammatory demyelinating polyneuropathy (CIDP) in adults.

Nov 13, 2024 - 06:00
Zai Lab and argenx announce NMPA approval for sBLA for VYVGART Hytrulo
Zai Lab and argenx have announced receipt of approval from the National Medical Products Administration (NMPA) of China for the supplemental biologics license application (sBLA) for VYVGART Hytrulo 1,000mg vial for treating chronic inflammatory demyelinating polyneuropathy (CIDP) in adults.
Read the original article

Tags:

Previous Article

IDWeek 2024: strategic approaches and challenges in mpox vaccination

Next Article

FDA grants breakthrough status to J&J’s nipocalimab for SjD treatment

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Opinion: AI-driven data analysis could exacerbate misaligned incentives in biomedical research

Opinion: AI-driven data analysis could exacerbate misal...

Sep 30, 2023

‘Stunning’ change to United’s colonoscopy coverage roils physicians and patients

‘Stunning’ change to United’s colonoscopy coverage roil...

May 15, 2023

Niacin has long been a public health darling. But an excess could be bad for the heart, study suggests

Niacin has long been a public health darling. But an ex...

Feb 19, 2024